Phase I trial of RV3-BB rotavirus vaccine: A human neonatal rotavirus vaccine

Vaccine

Volumn 31, Issue 23, 2013, Pages 2610-2616

  Danchin, M ^a,b   Kirkwood, C D ^a,c,d   Lee, K J ^a,d   Bishop, R F ^a,d   Watts, E ^a   Justice, F A ^a   Clifford, V ^a,b   Cowley, D ^a   Buttery, J P ^a,e,f   Bines, J E ^a,b,d  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MONASH CHILDREN S HOSPITAL   (Australia)

^f MONASH UNIVERSITY   (Australia)

Author keywords

Diarrhoea; Neonatal rotavirus vaccine; Rotavirus; RV3

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NECK PAIN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS INFECTION; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; COHORT STUDIES; DOUBLE-BLIND METHOD; FECES; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN A; INFANT; MALE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED; VIRUS REPLICATION; YOUNG ADULT;

EID: 84878351105     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.008     Document Type: Article

References (19)

1. WHO Strategic Advisory Group of Experts (SAGE) on Immunisation. Weekly epidemiological record. 2009;84th year(23):213-36.
2. Giaquinto C., Dominiak-Felden G., Van Damme P., Myint T.T., Maldonado Y.A., Spoulou V., et al. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccines 2011, 7(7):734-748. Epub 08/07/2011.
3. do Carmo G.M., Yen C., Cortes J., Siqueira A.A., de Oliveira W.K., Cortez-Escalante J.J., et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med 2011, 8(4):e1001024. Epub 29/04/2011.
4. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New Engl J Med 2010, 362(4):289-298.
5. Patel M., Pedreira C., De Oliveira L.H., Tate J., Orozco M., Mercado J., et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. J Am Med Assoc 2009, 301(21):2243-2251.
6. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):615-623.
7. Gladstone B.P., Ramani S., Mukhopadhya I., Muliyil J., Sarkar R., Rehman A.M., et al. Protective effect of natural rotavirus infection in an Indian birth cohort. New Engl J Med 2011, 365(4):337-346. Epub 29/07/2011.
8. WHO Strategic Advisory Group of Experts (SAGE) on Immunisation. Weekly epidemiological record. 2013;5(88):49-64.
9. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., et al. Intussusception among infants given an oral rotavirus vaccine. New Engl J Med 2001, 344(8):564-572. Epub 24/02/2001.
10. Bishop R.F., Barnes G.L., Cipriani E., Lund J.S. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. New Engl J Med 1983, 309(2):72-76.
11. Barnes G.L., Lund J.S., Adams L., Mora A., Mitchell S.V., Caples A., et al. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. J Paediatr Child Health 1997, 33(4):300-304.
12. Barnes G.L., Lund J.S., Mitchell S.V., De Bruyn L., Piggford L., Smith A.L., et al. Early phase II trial of human rotavirus vaccine candidate RV3. Vaccine 2002, 20(23-24):2950-2956.
13. Rickham P.P. Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. Br Med J 1964, 2(5402):177. Epub 18/07/1964.
14. Bishop R.F., Bugg H.C., Masendycz P.J., Lund J.S., Gorrell R.J., Barnes G.L. Serum, fecal, and breast milk rotavirus antibodies as indices of infection in mother-infant pairs. J Infect Dis 1996, 174(Suppl. 1):S22-S29.
15. Coulson B.S., Fowler K.J., Bishop R.F., Cotton R.G. Neutralizing monoclonal antibodies to human rotavirus and indications of antigenic drift among strains from neonates. J Virol 1985, 54(1):14-20. Epub 01/04/1985.
16. Tham E.B., Nathan R., Davidson G.P., Moore D.J. Bowel habits of healthy Australian children aged 0-2 years. J Paediatr Child Health 1996, 32(6):504-507. Epub 01/12/1996.
17. Anderson E.J. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis 2008, 8(10):642-649. Epub 17/10/2008.
18. Dennehy P.H., Goveia M.G., Dallas M.J., Heaton P.M. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis 2007, 11(Suppl. 2):S36-S42. Epub 08/03/2008.
19. Cherian T., Wang S., Mantel C. Rotavirus vaccines in developing countries: the potential impact, implementation challenges, and remaining questions. Vaccine 2012, 30(Suppl. 1):A3-A6. Epub 02/05/2012.